Marabese et al., in their study on non-small cell lung carcinoma (NSCLC), detected the highest mutation rate of KRAS at diagnosis Stage IV, and the G3 grade observed about 74% of mutated KRAS [34]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.